From: Characterizing pre-dialysis care in the era of eGFR reporting: a cohort study
 | Pre-eGFR/ PCP managed (n = 222) | Post-eGFR/ PCP managed (n = 159) | P-Value* (PCP managed, Pre vs. Post) | Pre-eGFR/ Co-managed (n = 52) | Post-eGFR/ Co-managed (n = 107) | P-Value* (Co- managed, Pre vs. Post) |
---|---|---|---|---|---|---|
Age (years) | 72.2 (12.5)†| 69.6 (13.0) | 0.05 | 63.3 (16.1)†| 67.3 (14.0) | 0.11 |
Female | 72.1% (160) | 62.9% (100) | 0.06 | 65.4% (34) | 57.9% (62) | 0.37 |
African-American | 22.5% (50) | 36.5% (58) | 0.0005 | 28.9% (15) | 41.1% (44) | 0.13 |
Diabetes | 30.2% (67) | 34.0% (54) | 0.25 | 38.5% (20) | 41.1% (44) | 0.75 |
Hypertension | 64.4% (143) | 75.5% (120) | 0.02 | 57.7% (30) | 86.0% (92) | < 0.0001 |
Insurance Status | Â | Â | Â | Â | Â | Â |
   Private | 30.6% (68) | 45.3% (72) | 0.009 | 40.4% (21) | 48.6% (52) | 0.67 |
   Medicare | 59.0% (131) | 49.1% (78) |  | 46.2% (24) | 41.1% (44) |  |
   Medical Assistance | 5.0% (11) | 4.4% (7) |  | 7.7% (4) | 7.5% (8) |  |
   Self-pay | 5.4% (12) | 1.3% (2) |  | 5.8% (3) | 2.8% (3) |  |
eGFR (ml/min/1.73 m2) | 37.2 (6.3)** | 35.5 (7.5)‡ | 0.02 | 31.4 (8.2)** | 31.0 (7.6)‡ | 0.78 |
Creatinine (mg/dl) | 1.71 (0.42)** | 1.83 (0.56)‡ | 0.02 | 2.18 (0.71)** | 2.19 (0.86)‡ | 0.94 |